Palvella Therapeutics (NASDAQ:PVLA) Rating Increased to Strong-Buy at Stephens

Palvella Therapeutics (NASDAQ:PVLA) was upgraded by equities research analysts at Stephens to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

PVLA has been the subject of several other research reports. Mizuho lifted their target price on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. TD Cowen reaffirmed a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. Chardan Capital lifted their target price on shares of Palvella Therapeutics from $210.00 to $240.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Wall Street Zen downgraded shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Stifel Nicolaus set a $250.00 target price on shares of Palvella Therapeutics in a report on Tuesday, February 24th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $199.53.

Palvella Therapeutics Stock Performance

Shares of PVLA stock opened at $125.79 on Tuesday. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -30.17 and a beta of -0.13. The company has a 50-day simple moving average of $125.41 and a 200 day simple moving average of $103.44. Palvella Therapeutics has a 52 week low of $20.20 and a 52 week high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Sell-side analysts forecast that Palvella Therapeutics will post -5.28 EPS for the current year.

Insider Buying and Selling at Palvella Therapeutics

In other Palvella Therapeutics news, Director Elaine J. Heron acquired 2,400 shares of the business’s stock in a transaction on Friday, February 27th. The stock was purchased at an average price of $125.00 per share, with a total value of $300,000.00. Following the acquisition, the director directly owned 47,812 shares of the company’s stock, valued at approximately $5,976,500. This trade represents a 5.28% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total transaction of $507,592.98. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 20.50% of the company’s stock.

Institutional Trading of Palvella Therapeutics

A number of institutional investors have recently bought and sold shares of the business. WCM Investment Management LLC bought a new stake in Palvella Therapeutics in the 1st quarter valued at about $4,982,000. KBC Group NV bought a new stake in shares of Palvella Therapeutics during the 1st quarter worth approximately $28,000. Swiss National Bank lifted its holdings in shares of Palvella Therapeutics by 36.6% during the 1st quarter. Swiss National Bank now owns 19,400 shares of the company’s stock worth $2,418,000 after acquiring an additional 5,200 shares during the period. Jennison Associates LLC lifted its holdings in shares of Palvella Therapeutics by 65.3% during the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock worth $79,852,000 after acquiring an additional 253,128 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Palvella Therapeutics by 10.9% during the 1st quarter. Bank of New York Mellon Corp now owns 18,041 shares of the company’s stock worth $2,249,000 after acquiring an additional 1,777 shares during the period. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.